Effects of galantamine on l-NAME-induced behavioral impairment in Y-maze task in mice

Neuroscience Letters

Volumn 462, Issue 3, 2009, Pages 235-238

  Tanaka, Ken ichi ^a   Yagi, Takao ^a,b   Shimakoshi, Ryosuke ^a   Azuma, Koji ^a   Nanba, Takeshi ^a,b   Ogo, Hiroya ^a,b   Tamura, Akiko ^a   Asanuma, Masato ^b  

^a SHUJITSU UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

Acetylcholine; Galantamine; l NAME; Nitric oxide; Working memory

Indexed keywords

GALANTAMINE; MECAMYLAMINE; N(G) NITROARGININE METHYL ESTER; NICOTINIC RECEPTOR; NITRIC OXIDE; NITRITE; SCOPOLAMINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; HIPPOCAMPUS; MALE; MAZE TEST; MEMORY DISORDER; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; WORKING MEMORY;

ANIMALS; BEHAVIOR, ANIMAL; CHOLINESTERASE INHIBITORS; GALANTAMINE; HIPPOCAMPUS; MALE; MAZE LEARNING; MECAMYLAMINE; MICE; MICE, INBRED ICR; NG-NITROARGININE METHYL ESTER; NICOTINIC ANTAGONISTS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NOOTROPIC AGENTS;

EID: 67849109650     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2009.07.024     Document Type: Article

References (33)

1. Arancio O., Kandel E.R., and Hawkins R.D. Activity-dependent long-term enhancement of transmitter release by presynaptic 3′,5′-cyclic GMP in cultured hippocampal neurons. Nature 376 (1995) 74-80
2. Bannerman D.M., Chapman P.F., Kelly A.T., Bucher S.P., and Morris R.G.M. Inhibition of nitric oxide synthase does not impair spatial learning. J. Neurosci. 14 (1994) 7404-7414
3. Bartus R.T., Dean III R.L., Beer B., and Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 217 (1982) 408-414
4. Bredt D.S., and Snyder S.H. Nitric oxide mediates glutamate linked enhancement of cGMP levels in the cerebellum. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 9030-9033
5. Chapman P.F., Atkins C.M., Allen M.T., Haley J.E., and Steinmetz J.E. Inhibition of nitric oxide synthesis impairs two different forms of learning. Neuroreport 3 (1994) 567-570
6. Chiueh C.C. Neuroprotective properties of nitric oxide. Ann. N.Y. Acad. Sci. 890 (1999) 301-311
7. Estevez A.G., Spear N., Thompson J.A., Cornwell T.L., Radi R., Barbeito L., and Beckman J.S. Nitric oxide-dependent production of cGMP supports the survival of rat embryonic motor neurons cultured with brain-derived neurotrophic factor. J. Neurosci. 18 (1998) 3708-3714
8. Farinelli S.E., Park D.S., and Greene L.A. Nitric oxide delays the death of trophic factor-deprived PC12 cells and sympathetic neurons by a cGMP-mediated mechanism. J. Neurosci. 16 (1996) 2325-2334
9. Garthwaite J., and Garthwaite G. Cyclic GMP and cell death in rat cerebellar slices. Neuroscience 26 (1988) 321-326
10. Garthwaite J., Garthwaite G., Palmar R.M.J., and Moncada S. NMDA receptors activation induces nitric oxide syntheses from arginine in rat brain slices. Eur. J. Pharmacol. 172 (1989) 413-416
11. Ibach B., and Haen E. Acetylcholinesterase inhibition in Alzheimer's disease. Curr. Pharm. Des. 10 (2004) 231-251
12. Knowles R.G., Palacios M., Palmar R.M.J., and Moncada S. Formation of nitric oxide from l-arginine in the central nervous system: a transduction mechanism for stimulation of the soluble guanylate cyclase. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 5159-5162
13. Lewin M.R., and Walters E.T. CyclicGMP pathway is critical for inducing long-term sensitization of nociceptive sensory neurons. Nat. Nature 2 (1999) 18-23
14. Maelicke A., Samochocki M., Jostock R., Fehrenbacher A., Ludwig J., Albuquerque E.X., and Zerlin M. Allosteric sensitization of nicotine receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol. Psychiatry 49 (2001) 279-288
15. Mamiya T., Noda Y., Noda A., Hiramatsu M., Karasawa K., Kameyama T., Furukawa S., Yamada K., and Nabeshima T. Effects of sigma receptor agonists on the impairment of spontaneous alternation behavior and decrease of cyclic GMP level induced by nitric oxide synthase inhibitors in mice. Neuropharmacology 39 (2000) 2391-2398
16. Mozayan M., Chen M.F., Si M., Chen P.Y., Premkumar L.S., and Lee T.J.F. Cholinesterase inhibitor blockade and its prevention by statins of sympathetic a7-nAChR-mediated cerebral nitrergic neurogenic vasodilation. J. Cereb. Blood Flow Metab. 26 (2006) 1562-1576
17. Nordberg A., and Svensson A.L. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. Drug Saf. 19 (1998) 465-480
18. Prickaerts J., de Vente J., Hong W., Steinbusch H.W., and Blockland A. cGMP, but not cAMP, in rat hippocampus is involved in early stages of object memory consolidation. Eur. J. Pharmacol. 436 (2002) 83-87
19. Prickaerts J., Steinbusch H.W., Smits J.F., and de Vente J. Possible role of nitric oxide-cyclic GMP pathway in object recognition memory: effects of 7-nitroindazole and zaprinast. Eur. J. Pharmacol. 337 (1997) 125-136
20. Sahrael H., Falahi M., Zarrindast M.R., Ghoshooni H., and Khalili M. The effects of nitric oxide on the acquisition and expression of nicotine-induced conditioned place preference in mice. Eur. J. Pharmacol. 503 (2004) 81-87
21. Takada Y., Yonezawa A., Kume T., Katsuki H., Kaneko A., Sugimoto H., and Akaike A. Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. J. Pharmacol. Exp. Ther. 306 (2003) 772-777
22. Takada-Takatori Y., Kume T., Sugimoto H., Katsuki H., and Akaike A. Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharmacology 51 (2006) 474-486
23. Takada-Takatori Y., Kume T., Sugimoto M., Katsuki H., Niidome T., Sugimoto H., Fujii T., Okabe S., and Akaike A. Neuroprotective effects of galantamine against glutamate neurotoxicity. Eur. J. Pharmacol. 549 (2006) 19-26
24. Thatcher G.R.J., Benett B.M., and Reynolds J.N. NO chimeras as therapeutic agents in Alzheimer's disease. Curr. Alzheimer Res. 3 (2006) 237-245
25. Tohgi H., Abe T., Kimura M., Saheki M., and Takahashi S. Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia. J. Neural. Transm. 103 (1996) 1211-1220
26. Troy C.M., Rabacchi S.A., Friedman W.J., Frappier T.F., Brown K., and Shelanski M.L. Caspase-2 mediates neuronal cell death induced by beta-amyloid. J. Neurosci. 20 (2000) 1386-1392
27. Wan Q., Luo Z.P., and Wang H. Muscarinic receptor activities potentiated by desensitization of nicotinic receptors in rat superiour cervical ganglia. Acta Pharmacol. Sin. 24 (2003) 657-662
28. Wang H.Y., Lee D.H.S., D'Andrea M.R., Peterson P.A., Shank R.P., and Reitz A.B. β-Amyloid (1-42) binds to α7 nicotinic acetylcholine receptor with high affinity: implications for Alzheimer's disease pathology. J. Biol. Chem. 275 (2000) 5626-5632
29. Wang D., Noda Y., Zhou Y., Mouri A., Mizoguchi H., Nitta A., Chen W., and Nabeshima T. The allosteric potentiation of nicotinic acetylcholine receptors by galantamine ameliorates the cognitive dysfunction in beta amyloid25-35 i.c.v-injected mice: involvement of dopaminergic system. Neuropsychopharmacology 32 (2007) 1261-1271
30. Yamada K., Hiramatsu M., Noda Y., Mamiya T., Murai M., Kameyama T., Komori Y., Nikai T., Sugihara H., and Nabeshima T. Role of nitric oxide and cyclic GMP in the dizocilpine-induced impairment of spontaneous alternation behavior in mice. Neuroscience 74 (1996) 365-374
31. Yamada K., and Nabeshima T. Modulation of nitric oxide production in vivo in the brain. Methods. Find. Exp. Clin. Pharmacol. 20 (1998) 601-605
32. Yamada K., Noda Y., Nakanishi S., Komori Y., Sugihara H., Hasegawa T., and Nabeshima T. Role of nitric oxide in learning and memory and monoamine metabolism in the rat brain. Br. J. Pharmacol. 115 (1995) 852-858
33. Zhuo M., Kandel E.R., and Hawkins R.D. Nitric oxide and cGMP can produce either synaptic depression of potentiation depending on the frequency of presynaptic stimulation in the hippocampus. Neuroreport 5 (1994) 1033-1036